Clinical trials: Pembrolizumab
Metastatic NSCLC
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
This is a non-randomized, Phase 2, 2-stage, open-label, multi-center study of GRN-1201/sargramostim + pembrolizumab in subjects with PD-L1+ metastatic NSCLC.
- Trial name
- NCT03417882
- Testing
- GRN-1201 + Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- BrightPath Biotherapeutics
Recurrent Glioblastoma
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
To learn if the Exablate Model 4000 Type 2 ("Exablate System") with the DEFINITY® ultrasound contrast agent can temporarily disrupt the blood brain barrier in patients with recurrent (has grown back) glioblastoma who are…
- Trial name
- NCT05879120
- Testing
- Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Advanced Melanoma
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of…
- Trial name
- NCT05549297
- Testing
- Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 540 people
- Sponsor
- Immunocore Ltd
Non-Small Cell Lung Cancer
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
- Trial name
- NCT03003468
- Testing
- Imprime PGG, MK-3475
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Lawrence Feldman, MD
Melanoma
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
This is an open-labelled single arm trial of pembrolizumab and imatinib mesylate in subjects with unresectable or metastatic KIT-mutant melanoma that are refractory to standard therapy.
- Trial name
- NCT04546074
- Testing
- Pembrolizumab and Imatinib mesylate
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Keio University
Neoplasms
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation.
- Trial name
- NCT03564691
- Testing
- MK-4830, Pembrolizumab, Carboplatin
- Where
- 37 sites in United States, Australia and 10 more
- Volunteers
- 470 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung…
- Trial name
- NCT04526691
- Testing
- Datopotamab deruxtecan, KEYTRUDA®, Carboplatin
- Where
- 24 sites in United States, Italy and 3 more
- Volunteers
- 145 people
- Sponsor
- Daiichi Sankyo
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Head and Neck Squamous Cell Carcinoma (HNSCC)
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with…
- Trial name
- KEYSTROKE (NCT03546582)
- Testing
- Pembrolizumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 18 sites in United States, Canada
- Volunteers
- 86 people
- Sponsor
- RTOG Foundation, Inc.
Hepatocellular Carcinoma
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC).
- Trial name
- NCT03006926
- Testing
- lenvatinib, pembrolizumab (200 mg)
- Where
- 26 sites in United States, France and 5 more
- Volunteers
- 104 people
- Sponsor
- Eisai Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC)…
- Trial name
- NCT06731478
- Testing
- Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab
- Where
- 250 sites in United States, Argentina and 24 more
- Volunteers
- 726 people
- Sponsor
- Daiichi Sankyo
Triple-negative Breast Cancer
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
The standard treatment for women with stage I, II, and III triple-negative breast cancer (TNBC) includes chemotherapy and surgery, with or without radiation therapy.
- Trial name
- NeoPACT (NCT03639948)
- Testing
- Carboplatin, Docetaxel, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Kansas Medical Center
Advanced Ovarian Cancer, Malignant Melanoma
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
This is a phase 1b study for patients with metastatic (cancer has spread to various parts of the body) melanoma and ovarian cancer.
- Trial name
- ACTIVATE (NCT03158935)
- Testing
- Cyclophosphamide, Fludarabine, Pembrolizumab
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
TNBC - Triple-Negative Breast Cancer
Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)
The purpose of this study is to evaluate the treatment outcomes and safety of neoadjuvant therapy including pembrolizumab in real-world practice for patients with triple-negative breast cancer (TNBC) in a multi-center study in…
- Trial name
- NCT07828652
- Testing
- Medical record use research
- Volunteers
- 2,000 people
- Sponsor
- Yeon Hee Park
Melanoma, Non-small Cell Lung Cancer
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
The purpose of this phase 2 trial is to study the activity of pembrolizumab in combination with bevacizumab in patients with untreated brain metastases from melanoma or NSCLC to determine activity and safety of the drug…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
- Trial name
- NCT02681549
- Testing
- Pembrolizumab plus Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Bladder Cancer, Gastric Cancer
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies.
- Conditions
- Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT04383938
- Testing
- APR-246 (eprenetapopt) + Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aprea Therapeutics
Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma.
- Trial name
- NCT05147558
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Melanoma
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
There is a new form of cancer treatment called immunotherapy which does not attack cancer directly but works on the immune system to make it more effective.
- Trial name
- PASIP (NCT02909348)
- Testing
- Pembrolizumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Colorectal Cancer Metastatic
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated.
- Trial name
- NCT06634875
- Testing
- isunakinra
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Buzzard Pharmaceuticals
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.